Accessibility Menu
BioAtla logo

BioAtla(NASDAQ) BCAB

Current Price$3.36
Market Cap$5.74MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-100%
5 Year-100%
1 Year-83%
1 Month-3%
BioAtla last closing stock price
MetricPriceDate
Last closeUSD 3.462026-07-23
BioAtla stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-13.28%USD 3.992026-07-16
1 month-3.08%USD 3.572026-06-23
3 month-28.95%USD 4.872026-04-24
Year to date-87.81%USD 28.392025-12-31
1 year-82.69%USD 19.992025-07-23
3 year-97.6%USD 144.002023-07-24
5 year-99.83%USD 2,063.502021-07-23
Since inception-99.78%USD 1,551.002020-12-16

BioAtla Financials at a Glance

Market Cap

$5.74MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$2.00M

Net Income (TTM)

-$50.62M

EPS (TTM)

-$41.83

P/E Ratio

-0.08

Dividend

$0.00

Beta (Volatility)

1.75 (High)

Price

$3.36

Volume

541

Open

$3.31

Previous Close

$3.36

Daily Range

$3.27 - $3.36

52-Week Range

$3.12 - $71.50

Estimated Earnings Date

Aug 6, 2026

BCAB News

Foolcom-Featured.png

BioAtla (BCAB) Q2 Loss Narrows 27%

Motley Fool Markets TeamAug 7, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BioAtla

BioAtla develops targeted cancer therapies for people with solid tumors. Its medicines aim to attack cancer cells while sparing healthy tissue. These treatments help patients by reducing side effects from traditional cancer drugs.

Products and Services

  • Antibody-Drug Conjugates: Engineered antibodies deliver cancer-killing drugs directly to tumor cells.
  • Immuno-Oncology Agents: Antibodies designed to boost the body’s immune response against cancer.
  • Bispecific Antibodies: Molecules that connect immune cells to cancer cells for targeted attack.
  • Licensing and Collaboration: Revenue from milestone payments and partnerships with other drug companies (100% of 2025 revenue).

Growth and Expansion

  • 2025: Entered licensing agreement with Context Therapeutics for a new cancer therapy.
  • 2022: Began clinical trial collaboration with Bristol-Myers Squibb for combination cancer treatments.
  • 2025: Signed Standby Equity Purchase Agreement with Yorkville to raise capital.
  • 2026: Launched formal review to explore asset sales, licensing, and partnerships.
  • 2026: Reduced workforce by 70% to preserve cash and focus on core programs.

What Makes BioAtla Stand Out

BioAtla’s technology activates cancer drugs only in tumor environments, aiming to reduce harm to healthy cells. The company holds a large patent portfolio, supporting its proprietary approach. It relies on third-party manufacturers and focuses on partnerships to advance its pipeline.

Five Things You Need to Know

  • Revenue was $2.0 million in 2025, down 81.8% from 2024.
  • Net loss was $59.6 million in 2025, improving 14.6% from 2024.
  • Cash and cash equivalents were $7.1 million at December 31, 2025.
  • Operating expenses fell 27.8% to $61.3 million in 2025.
  • All 2025 revenue came from licensing, not product sales.

Bottom Line

BioAtla is adapting through cost cuts and partnerships as it seeks new funding. The company’s focus remains on developing targeted cancer therapies using its proprietary technology.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

41

CEO

Jay M. Short, PhD

Website

www.BioAtla.com

Headquarters

San Diego, CA 92121, US

BCAB Financials

Key Financial Metrics (TTM)

Gross Margin

-371.00%

Operating Margin

-2524.95%

Net Income Margin

-2530.85%

Return on Equity

166.67%

Return on Capital

N/A

Return on Assets

-590.91%

Earnings Yield

-12.50%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$5.74MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.66M

Volume

541

Avg. Volume

49.76K

Financials (TTM)

Gross Profit

-$7.42M

Operating Income

-$50.50M

EBITDA

-$47.79M

Operating Cash Flow

-$37.18M

Capital Expenditure

$0.00

Free Cash Flow

-$37.18M

Cash & ST Invst.

$1.96M

Total Debt

$6.09M

BioAtla Performance Analysis

BioAtla annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 11,000,000N/A
20252025-12-31USD 2,000,000-81.8%
BioAtla sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31-100.0%
BioAtla annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -136.77-0.9%
20232023-12-31USD -129.21-5.5%
20242024-12-31USD -71.83-44.4%
20252025-12-31USD -50.66-29.5%
BioAtla sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-23.1%
Q32025-09-3015.6%
Q42025-12-3140.7%
Q12026-03-3147.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$120.00K

+34.4%

Gross Margin

0.00%

N/A

Market Cap

$5.74MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$140.05K

N/A

Employees

41

N/A

Net Income

-$6.34M

+58.6%

EBITDA

-$6.22M

+58.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$1.96M

-93.9%

Total Debt

$6.09M

+1000.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$4.54M

N/A

Short Term Debt

$1.56M

+181.4%

Return on Assets

-5.91%

N/A

Return on Invested Capital

4.16%

N/A

Free Cash Flow

-$5.27M

+67.7%

Operating Cash Flow

-$5.27M

+67.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RVPHReviva Pharmaceuticals Holdings, Inc.
$0.53+11.71%
CELUCelularity Inc.
$0.75-1.32%
EVAXEvaxion Biotech A/S
$2.96-2.95%
BTAIBioXcel Therapeutics, Inc.
$0.85-2.62%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
NUNu Holdings
$14.09-0.01%
FFord Motor Company
$14.37+0.02%
AALAmerican Airlines Group
$14.48+0.07%

Questions About BCAB

What is the current price of BioAtla?

BioAtla is trading at $3.36 per share.

What is the 52-week range for BioAtla?

Over the past 52 weeks, BioAtla has traded between $3.12 and $71.50.

How much debt does BioAtla have?

As of the most recent reporting period, BioAtla reported total debt of $6.09M.

How much cash does BioAtla have on hand?

BioAtla reported $1.96M in cash and cash equivalents in its most recent financial results.

What is BioAtla’s dividend yield?

BioAtla does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services